Treatment of murine colitis by Lactococcus lactis secreting interleukin-10

被引：1130

作者：

Steidler, L

Hans, W

Schotte, L

Neirynck, S

Obermeier, F

Falk, W

Fiers, W

Remaut, E

机构：

[1] Univ Ghent, Dept Mol Biol, B-9000 Ghent, Belgium

[2] Flanders Interuniv Inst Biotechnol, B-9000 Ghent, Belgium

[3] Univ Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany

来源：

SCIENCE | 2000年 / 289卷 / 5483期

关键词：

D O I：

10.1126/science.289.5483.1352

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bower disease (IBD), Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by Localized delivery of a bacterium genetically engineered to secrete the cytokine, Intragastric administration of IL-10-secreting Lactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10(-/-) mice. This approach may Lead to better methods for cost-effective and Long-term management of IBD in humans.

引用

页码：1352 / 1355

页数：4

共 29 条

[1] Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses [J].